trending Market Intelligence /marketintelligence/en/news-insights/trending/GZ_SXQlKVSJzWd2gBHdKRg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BIO Asia: Sinorda aims to go public in 2 years; to close A round financing in H1

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

BIO Asia: Sinorda aims to go public in 2 years; to close A round financing in H1

Sinorda Biomedicine Ltd. aims to go public in 2020 or 2021, Chairman Hu Pingsheng told S&P Global Market Intelligence on the sidelines of the 2019 BIO Asia International conference in Tokyo.

Hu said the company is in talks with investment banks and will prioritize listing in Hong Kong and on the new Shanghai trading board.

The Hong Kong stock exchange in April last year eased listing rules to enable pre-revenue biotech companies go public. The Shanghai Stock Exchange will follow suit in a bid to attract biotech startups with similar relaxed rules.

Hangzhou-based Sinorda has more than five drugs under clinical study, according to Hu. The company completed a phase 1 study in Europe for one of its main products for gastric acid-related diseases, X842. Sinorda expects to finish a phase 1 for the drug in China soon, and a phase 2 study in 2020.

Sinorda is also in talks to in-license anti-inflammatory drugs.

Further, Hu said the company plans to complete an A round financing of about US$200 million to US$300 million in April or May, and will start a new round of financing by the end of 2019.